Pregnancy hormones may speed up cannabis processing, study finds
NCT ID NCT04374773
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how two hormones that rise during pregnancy—estradiol and cortisol—affect the way the body breaks down THC, the main active ingredient in cannabis. Fourteen healthy women of childbearing age took part. Researchers measured THC levels in the blood after taking a synthetic THC pill (dronabinol). The goal was to better understand how cannabis use might affect pregnant women and their developing babies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
14 people
The number who actually took part.
- Started
-
Oct 2020
- Finished
-
Feb 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 45 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthy, premenopausal women ages 21-45 years old * Body mass index (BMI) \<30 kg/m2 * Regular menstrual periods (monthly, cycle 28-35 days in length) * Willingness to use nonhormonal methods of contraception during the study period Exclusion Criteria: * History of diabetes or significant cardiac, kidney (eGFR\<60 mL/min/1.73m2), gastrointestinal or liver disease * History of blood clots or stroke * Allergy to dronabinol, synthetic steroids, or any other chemically related drug or steroid * Current or recent ingestion (\<3 weeks) of any medication or herbal supplement known to be an inducer or inhibitor of CYP2C9, CYP3A4 or UGT. These include some anticoagulants, anti-psychotics, antibiotics, antifungal agents, antidepressants, anti-retroviral agents and herbal supplements (or other over-the-counter medications and supplements). Subjects who are taking any of these prescription drugs will not be asked to discontinue treatment but will be ineligible for study participation. Subjects taking excluded over-the-counter medications and/or supplements will be given the option of discontinuing these for 1 month prior to study participation. * Current pregnancy or lactation * History of use of illicit drugs or smoking within the last year * Any recreational or medicinal use of cannabis or other forms of THC within 3 months * Current use of amphetamines, anticholinergic drugs or antidepressants * History of seizure disorder or psychiatric illness (mania or schizophrenia; major depression within the past year or \>2 episodes lifetime) * Current use of live or live attenuated vaccines * Personal or family (1st degree relative) history of breast or ovarian cancer * Systemic disease (cancer, auto-immune disease, chronic infection, etc) * Current or recent (within 6 months) use of hormonal contraceptives * History of severe hypertriglyceridemia (\>300 mg/dL or history of acute pancreatitis) * Uncontrolled hypertension (BP\>140/90) * Allergy to sesame oil * Anemia (Hct \<34 g/dL) * Extensive skin disease (eczema, psoriasis, etc) that would preclude use of transdermal estradiol
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cannabis use are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nina Isoherranen
Seattle, Washington, 98125, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a TB infection leave a mark on the placenta?
- Can a short tobacco break curb cannabis cravings?
- Can a newer hepatitis b drug protect babies while being gentler on their bones?
- Can virtual mindfulness groups support pregnant individuals at risk?
- Can surveillance catch birth defects early in HIV-Affected pregnancies?
- Texting teens to tame risky drinking and weed use?